| 乳腺癌多西他赛耐药的分子机制 |
| |
| 引用本文： | 吴新刚,黄谦,向安萍. 乳腺癌多西他赛耐药的分子机制[J]. 肿瘤防治研究, 2014, 41(4): 413-415. DOI: 10.3971/j.issn.1000-8578.2014.04.029 |
| |
| 作者姓名： | 吴新刚 黄谦 向安萍 |
| |
| 作者单位： | 414000 湖南岳阳，岳阳职业技术学院医学基础部 |
| |
| 基金项目： | 湖南省教育厅基金资助项目（11C1284） |
| |
| 摘 要： | 多西他赛（DTX）已广泛应用于乳腺癌的辅助化疗、新辅助化疗和转移性乳腺癌的治疗。然而, 由于天然耐药的存在和获得性耐药的产生，严重制约了DTX的临床应用。已知的乳腺癌多西他赛的耐药机制主要包括：药物作用靶点的改变、解毒酶的激活、细胞凋亡相关基因的异常表达、DNA甲基化状态、ATP结合盒（ABC）转运蛋白的过表达、微小RNA的表达异常等。
|
| 关 键 词： | 多西他赛 乳腺肿瘤 多药耐药 |
| 收稿时间： | 2012-12-31 |
Molecular Mechanisms of Docetaxel Resistance in Breast Cancer |
| |
| WU Xingang,HUANG Qian,XIANG Anping. Molecular Mechanisms of Docetaxel Resistance in Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2014, 41(4): 413-415. DOI: 10.3971/j.issn.1000-8578.2014.04.029 |
| |
| Authors: | WU Xingang HUANG Qian XIANG Anping |
| |
| Affiliation: | Department of Basic Medical Sciences,Yueyang Vocational Technical College,Yueyang414000,China |
| |
| Abstract: | Docetaxel has been used widely for the treatment of breast cancer in neoadjuvant, adjuvant andmetastatic settings. However, its therapeutic usefulness is limited by innate or acquired resistance. The knownmechanisms of docetaxel resistance in breast cancer include the alteration of drug target, the activation ofdetoxifying enzymes, the aberrant expression of apoptosis-related genes, the DNA methylation status, theoverexpression of the ATP-binding cassette transporters, and the abnormal microRNA expression. |
| |
| Keywords: | Docetaxel Breast cancer Multidrugresistance |
|
| 点击此处可从《肿瘤防治研究》浏览原始摘要信息 |
|
点击此处可从《肿瘤防治研究》下载全文 |
|
